Cardiometabolic diseases such as heart disease, stroke and diabetes are no longer “Western” diseases confined to developed nations. The rapidly growing economies and Westernized lifestyles of emerging nations in Asia, Latin America and Eastern Europe are characterized by increasing incidence of chronic diseases.
WHO projects that more than 80% of cardiometabolic deaths occur in low- and middle-income countries where people are exposed to more risk factors (such as unhealthy diet and smoking), and have less access to effective treatments (drugs such as statins and medical devices such as pacemakers and prosthetic valves). WHO estimates that cardiometabolic diseases will reduce the gross domestic product of emerging nations by 1% to 15% (total). Heart disease, stroke and diabetes are projected to cost China $558 billion in national income between 2006 and 2015.
In the United States, the Centers for Disease Control and Prevention (CDC) report more than 800,000 deaths and 2 million heart attacks and strokes annually, with costs of more than $444 billion in care services and lost productivity. However, these diseases will take a much greater toll as the aging baby boomer generation doubles the number of elderly in the U.S.; by 2030, nearly 20% of the population—more than 72 million people—will be 65 or older. Adding to the demographic burden, dramatic increases in obesity and diabetes put ever-larger populations at risk. According to CDC estimates, obesity affects one in three Americans, nearly double the number of obese adults in 1980. Worldwide diabetes incidence is projected to soar from 366 million people in 2011 to 552 million by 2030.
Cardiometabolic therapeutic innovation is clearly a global enterprise. Multinational trials are developing new therapies and devices across a divergent research landscape, from the mature markets of North America and the European Union to emerging markets in Latin America, Eastern Europe and the Asia Pacific.
Clinipace Worldwide can help you conduct successful multinational studies by gaining operational proficiencies and ensuring consistencies across local regulatory requirements, treatment landscapes and varying standards of care. By making the best use of our unified technology platform, TEMPO™ eClinical, we enable integration and collaboration among functions across the spectrum of clinical trials operations country-by-country.